Investor presentation - path to cashflow breakeven
Released
Released
Announcement PDF
Building the platform
for personalised,
microbiome-based
healthcare
Equity Raise Presentation
Authorised for release by the Board of Directors
Not for release to US wire services or distribution in the United States
ASX: MAP
12 JUNE 2026
1
Disclaimer
This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba).
Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or
supplement this presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that
would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act).
Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry
or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also
based on the good faith estimates of Microba, which are derived from its reviews of internal sources as well as the independent sources described above.
Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an
invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe
such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.
Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared
without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should
make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and
particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.
Future performance - This Presentation contains forward looking statements and includes forward financial information (Forward Looking Statements) Forward Looking Statements generally relate to current expectations, hopes, beliefs, intentions,
strategies or projections about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and
services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify Forward Looking Statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible",
"project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that
a statement is not forward-looking. Such Forward Looking Statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such Forward Looking Statements.
These Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside
the control of Microba. You are cautioned not to place undue reliance on any Forward Looking Statements. Forward Looking Statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Refer to
slide 29 for details of the assumptions and risks underpinning the Forward Looking Statements that consists of the forward financial information contained in this Presentation.
Actual results, performance or achievements may vary materially from any Forward Looking Statements and the assumptions on which statements are based. The Forward Looking Statements in this Presentation are based on information available to Microba
as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking
statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.
Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical, pro-forma and forward financial information. The historical financial information for the 12 months ended
30 June 2025 has been prepared based on audited financial information. The historical financial information for the 6 months ended 31 December 2025 has been prepared based on reviewed financial information. The historical financial information provided in
this Presentation is for illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance.
Also included is forward financial information relating to Microba being break-even by the end of calendar year 2027 (CY2027) ("CY2027 Forward Financial Information"). Refer to slide 29 for details of the assumptions underpinning the CY2027
Forward Financial Information. The CY2027 Forward Financial Information is provided on the basis of the general 'forward performance' disclaimer on Forward Looking Statements, as detailed above.
Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this
Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.
Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage
which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or
completeness of this Presentation.
2
A focused, growing, defensible business on
path to cashflow break-even
Streamlined
A structurally lower
cost base
Growth
Continued sales
growth
Margin
Operating leverage over
infrastructure in place
Break-even
A clear path to
cashflow break-even
Supported by this equity raise.
3
Investment highlights
1 Market sizing assumptions and methodology are outlined in detail on Slide 30.
2 Refers to specialist Boston-based advisor engagement mandate and active partnering process, for the avoidance of doubt no partnering agreement has been entered into as at the date of this presentation
Delivering cashflow
break-even
This capital raise plus
streamlined, AI efficient
operations delivering
break-even for the whole
company in CY2027 on a
run rate basis.
Large addressable
market with latent
demand
$25B1 initial TAM
addressing 82 million
patients p.a. with
gastrointestinal disease.
Clinicians and patients are
seeking an effective,
clinical-grade solution.
Accelerating sales
and customer
adoption
Core Testing products
have delivered 11
consecutive quarters of
growth, over 100% YoY
sales growth, reaching a
23,000+ annualised test
run rate in Q3 with a
pipeline of 22,000+ in
incremental annual volume
potential recently signed
Expanding
operating leverage
2027 is set to be a
breakout year for operating
leverage, delivering rapid
acceleration in revenue per
employee leveraging
recently completed product
and infrastructure
investments, and company
wide AI-efficiencies
Therapeutics
primed to partner
Following multiple recent
positive clinical trial
readouts and over $100m
investment for the sector,
Microba’s Therapeutics
division is active in a
partnering process with a
Boston-based specialist
advisory firm2.
4
MICROBA.COM EXPECT BETTER
MICROBA.COM
EXPECT BETTER
MICROBA LIFE SCIENCES LTD
© ALL RIGHTS RESERVED
Strong Diagnostics
growth outlook
Section 1
5
Strong, continuous sales growth
$0
$500,000
$1,000,000
$1,500,000
$2,000,000
$2,500,000
$3,000,000
FY2023-Q3
FY2023-Q4
FY2024-Q1
FY2024-Q2
FY2024-Q3
FY2024-Q4
FY2025-Q1
FY2025-Q2
FY2025-Q3
FY2025-Q4
FY2026-Q1
FY2026-Q2
FY2026-Q3
11 consecutive Quarters of QoQ
Core Testing Sales growth
11 Consecutive quarters of total Core Testing Sales growth
9x Cumulative growth in Core Testing Sales (FY2023-Q4 to FY2026-Q3)
106% Growth in Last 12 months Core Testing Sales (latest 4 quarters vs prior 4)
6
Organic growth set to continue
99%
Core testing revenue growth YoY (Q3 FY26)
Organic growth momentum across both core markets
• Australia: adoption has moved beyond innovators into early adopters via
enterprise-style clinic contracts with recurring volume potential.
• United Kingdom: testing market has outperformed Australia at the equivalent
time post-launch, leveraging the acquired Invivo base.
23,000+
Annualised core test run rate base (Q3 FY26)
+22,000
Volume potential from new enterprise-style
accounts signed between Q2 and Q4
Category defining new product set to launch in Q3 CY26
• Major next growth catalyst set to drive adoption with mainstream
medical professionals together with Sonic and SYNLAB
Enterprise-style contracts with healthcare clinics driving next level of
growth
• Over 130 key account targets currently in the pipeline in Australia, with
an estimated ordering potential of over 60,000 tests per annum. Since
Q2 FY26 we have already signed 34, representing a total estimated
ordering potential of over 22,000 tests per annum1.
7
1 Refers to signed corporate payment terms and volume-based pricing agreements
Category defining new testing
product set to launch in Q3 CY26
• World-first complete microbiome and GI test
• Designed to support the 40% of people living with an unresolved GI disorder2
• Makes result interpretation quick and easy for all healthcare professionals3
• Powered by Microba’s Clinical Intelligence and advanced clinical decision support system
8
1 For use by Health Care Professional as a clinical decision supporttool
2 Sperber et al. Gastroenterology,2021
3 Treatment plans are to be determined by the treating healthcare professional. Diagnostic insights are intended to inform, not replace, clinical judgement.
Supporting the resolution of complex GI symptoms –
with easy-to-use clinical intelligence powered by the
latest microbiome science1
MICROBA.COM EXPECT BETTER
MICROBA.COM
EXPECT BETTER
MICROBA LIFE SCIENCES LTD
© ALL RIGHTS RESERVED
Delivering cashflow
break-even
Section 2
9
Each lever closes part of the gap from $1.3m monthly burn to break-even in CY2027 – delivered on infrastructure already invested, leveraging strong sales momentum.
Break-even built on infrastructure already in place
1
Sales & marketing efficiencies
Reducing customer acquisition cost from AI-supported customer targeting and
marketing, a unified global brand, automated lifecycle marketing and self-serve
signup.
2
Cost reductions & operational efficiencies
AI automation across customer support, HR, legal and finance structurally lowers
cost to serve as we scale.
3
Engineering, science & product efficiency
Major new product build about to complete. In addition, AI-supported product,
evidence and software development systems cut engineering and product cost
per release.
4
Sales growth & margin expansion
Rising volume on a fixed cost base, with margin expansion from pricing power,
scaling economics and operational efficiency.
$1.3m / month
Current monthly burn
– ~$700k
Cost reductions & efficiencies
+ ~$600k
Growth in revenue & contribution margin on fixed cost base
Break-even
The information on this slide includes forward financial information (Forward Financial Information). The Forward Financial Information has been prepared by Microba Life Sciences Ltd based on management best estimate assumptions
which relate to future event(s) that Microba expects to occur and actions that Microba expects to take and are also subject to uncertainties and contingencies, which are often outside the control of Microba. While all reasonable endeavours
have been made to ensure both the robustness of the assumptions on which the Forward Financial Information is based and that such assumptions are true, complete and accurate, such assumptions are generally future-oriented and
therefore speculative in nature. 'Refer to slide 24 - 29 ('Key Risks and Forward Financial Information Assumptions') for detail on both the assumptions and risks underpinning the CY27 numbers.
Cashflow break-even on a run rate basis for the whole company
in CY2027 leveraging infrastructure already in place
10
Rapid advancement in revenue per employee
1) Strong organic growth
momentum leveraging years of
market development and
latent potential in customer
pipeline
2) Streamlined operations
leveraging recent infrastructure
investments together with AI
efficiency across product,
marketing, customer service,
engineering and operations
3) Market leading products with
defensible technology, clinical
accreditation and proprietary
clinical-grade data moats.
HOW DO WE GET THERE?
136
136
150
158
234
235
328
426
429
438
450
473
547
582
597
695
743
0 100 200 300 400 500 600 700 800
4D Medical
Microba — today
Healius
Australian Clinical Labs
Pacific Edge
Sonic Healthcare
Microba — FY27 target
Cochlear
PolyNovo
Nanosonics
Microba — next target
Myriad Genetics
Medtronic
Natera
Abbott
Stryker
ResMed
Revenue per employee (A$'000)
Revenue per employee for companies other than Microba is based on management's review of publicly available data sources, including company annual reports, regulatory filings and third-party financial data providers. Figures reflect each
company's most recent full financial year and have been converted to Australian dollars at indicative exchange rates as at 7 June 2026. Employee numbers are drawn from the most recent available disclosures or estimates and may reflect
total headcount rather than full-time equivalents. These figures are indicative only, have not been independently verified, and are presented to illustrate relative positioning across peer groups rather than as precise comparisons. Microba's
figures are management best estimates. CY2027 targets are based solely on achieving cashflow break-even in CY 2027, management's best estimates of employee numbers in that year and are subject to the risks and assumptions referred
to in this Presentation. Subsequent targets are aspirational only and are subject to the risks and assumptions referred to in this Presentation.
Top tier molecular
diagnostics & devices
ResMed, Stryker, Abbott,
Natera, Medtronic, Myriad
Genetics
Strong molecular
diagnostics & devices
Nanosonics, PolyNovo,
Cochlear
Pathology & emerging
diagnostics
Sonic Healthcare, Pacific
Edge, Australian Clinical
Labs, Healius, 4D
Medical
Microba CY2027
Microba Today
Microba Next Target
11
Total Addressable Market
The entire pie
7 major markets. 1 indication – GI disorders. Established in clinical
practice guidelines with reimbursement, routine use.
TAM
$25B
82m tests p.a.
Serviceable Addressable Market
SAM
18m tests pa
Serviceable Obtainable Market
The slice of the pie we can target in the near term.
Top 5 focus markets. 1 indication – GI disorders.
Innovators into early majority.
The portion of that slice we expect to eat in the near term
Top 5 focus markets. 1 indication – GI disorders.
Innovators & early adopters only. Cash pay only.
100%
22%
2%
Future Addressable Market
All flavours of pie.
7 major markets. Top 10 indications. Established in clinical practice
guidelines with reimbursement, routine use for GI disorders.
Est. 729m tests p.a. / $125B
SOM
2m tests p.a.
Top-down, bottom up, primary, secondary and tertiary
research methodologies were used to quantify the market size
800%
The market is big, and we only
need to capture a small amount to
impact at scale
We are here today
Market sizing assumptions and methodology are outlined in detail on Slide 30. 12
Five pillars driving, durable, scalable, AI powered growth
1
Large-scale latent
demand
Growing clinical evidence
is driving acceptance of the
microbiome. Clinicians and
patients are ready to adopt
clinical-grade solutions
they can trust.
2
Efficient growth
engines
A product-accelerated
growth model — self-serve
signup, always-on funnels,
automated lifecycle
marketing, AI support —
scales beyond a 1:1 sales
force.
3
Essential clinical
utility
A technically rich, self-
describing report delivers
clear insights and actions,
making microbiome testing
usable without specialist
training.
4
Recurring, sticky
revenue
A technology-led
experience supports
clinicians and patients from
referral to adherence,
owning the relationship,
lowering customer
acquisition cost and lifting
lifetime customer value.
5
Powerful moats
Proprietary measurement
methods, bioinformatics IP,
accreditation and a
growing clinical-grade
dataset compound into
durable competitive
advantage.
13
MICROBA.COM
EXPECT BETTER
MICROBA LIFE SCIENCES LTD
© ALL RIGHTS RESERVED
Therapeutics primed
to partner
Section 3
14
Significant recent momentum in microbiome therapeutics
Live biotherapeutics validated in multiple chronic disease settings by clinical readouts
Dec 2025
Successful Pivotal Phase 3 in graft-versus-host disease2
Positive final pivotal results. Under regulatory review by the European
Medicines Agency for Market Approval – decision expected mid-2026.
Feb 2026
Successful Phase 1b readout in inflammatory bowel disease4
First-in-Human trial, COMPOSER-1, for MB310 in UC patients. End points
met.
Jan 2026
Successful Phase 2a in Irritable Bowel Syndrome3
Enterobiotix - Phase 2a TrIuMPH trial, for EBX-102-02 in irritable bowel syndrome
(IBS) patients
1 https://www.prnewswire.com/news-releases/siolta-therapeutics-reports-positive-phase-2-results-from-the-adored-study-302616190.html, 2 https://www.maatpharma.com/december-8-2025-
maat-pharma-presents-pivotal-ares-phase-3-results-for-maat013-xervyteg-in-acute-gvhd-at-ash-2025-annual-congress-and-announces-54-1-year-overall-survival/ , 3
https://www.enterobiotix.com/news/phase-2a-results-with-ebx-102-02, 4 https://microbiotica.com/microbiotica-announces-impressive-results-in-its-phase-1b-trial-of-mb310-in-ulcerative-colitis/
Nov 2025
Successful Phase 1b/2 readout in allergic disease1
Randomised, double-blind, multi-centre study to evaluate the preliminary clinical
efficacy of STMC-103H in neonates and infants at risk of developing allergic disease
Commentary
• Multiple microbiome
therapeutics sector read
outs delivered between Nov-
25 and Feb-26 validating the
modality across multiple
chronic diseases for pharma
partners
• Microba's Therapeutics
division is active in a
partnering process with a
Boston-based advisor for its
field-leading assets
15
Recent sector investment
Recent capital raises by peer microbiome therapeutic companies are validating the appetite for these assets
Sep 2025 – Series B
US$64.1M raised at a
post-money valuation of
US$253M
Mar 2023 - Venture /
Grant
US$2.1M grant (€2M)
raised by SFPIM;
Agentschap Innoveren &
Ondernemen (grant)
Belgian biopharma developing
live biotherapeutic products
from the human microbiome
April 2026 – Series A
extension
US$12.0M (€12M) raised
at a post-money
valuation of $94.3M by
Bayern Kapital and MIG
Fonds
Mar 2023 - Series A
US$14.1M (€13M) raised
at a post-money
valuation of US$68.2M
by MIG Capital (lead),
HTGF, and Bayern
Kapital
German biotech advancing
microbiome-derived
therapeutics
April 2026 – Venture
US$25.7M (£19M) raised
by Scottish National
Investment Bank &
Thairm Bio (co-leads)
April 2024 - Venture
(top-up)
US$34m (£27m) raise by
Thairm Bio, Kineticos Life
Sciences, and Scottish
National Investment
Bank
Scottish developer of
microbiome-based medicines to
restoring gut health and
preventing bacterial infections
May 2026 – Series A
US$48.0M raised at a
post-money valuation of
US$239.7M by DCVC and
Lions Capital LLC (co-
leads) and others
Jul 2024 - Series A
US$12.5M raised at a
post-money valuation of
US$79.7M by Kicker
Ventures & Gates
Foundation (co-leads);
Pangaea Ventures and
others
US platform mapping microbial
interactions for therapeutic
discovery
Notes: USD conversionsreflect FX on announcementdate as recorded by Crunchbase;post-moneyvaluations rounded.
Sources: Crunchbase,Pitchbook,company press releases (Sep 2025 – May 2026).
Feb 2026 – 3rd Series B
~US$7.5M (¥1.19B)
raised by a total of seven
companies including
Asuka Pharmaceutical,
Canon Marketing Japan
MIRAI Fund and others
Sep 2025 - 1st & 2nd
Series B
US$15M (~¥2.32B) raised
by four new global
investors alongside
seven existing backers
Japanese microbiome
therapeutics platform advancing
precision medicine through
faecal transplantation
16
Portfolio is ready to transact and advance
Core Program Discovery R&D Preclinical Phase 1 Phase 2 Development Partners
IBD
Ulcerative Colitis (UC)
MAP 315 (LBP)
Undisclosed (LBP)
IO
Immuno-oncology
MAP 315 (LBP)
Undisclosed (LBP)
Autoimmune Undisclosed (LBP)
Phase 2 ready
Pre-clinical biology
supporting lead
candidate selection
Laboratory & animal
model experiments
confirming activity
Diversified portfolio of microbiome-derived live biotherapeutic products (LBPs) — active in a partnering process with a Boston-based advisor
Fast follow IO programme – rapid Phase 1b
MAP 315 - Phase 1b in patients with immunotherapy-
induced colitis - one of the most common and
clinically significant adverse events which occurs in
∼15-30% of patients on combination regimens3.
De-risked lead IBD programme – Phase 2 ready
MAP 315 – Phase 2-ready oral-capsule Live
Biotherapeutic Product (LBP) for mild-to-moderate
UC, a US$10bn+ market where 30% to 60%2 of
patients are under-served.
Asset pipeline breadth
Multiple assets across IBD, autoimmune and
immuno-oncology, already well advanced.
Microba’s repeatable data-driven AI/ML drug
discovery platform has already identified novel
therapeutic leads across 18 diseases.
Ready to move
rapidly into Phase 1b
1 EvaluatePharma, 2 Ham et al, Expert Rev Clin Pharmacol (2012),3 Tran et al. Journal of Immunotherapy (2021), Yin et al. Front Immunol (2023) 17
MICROBA.COM EXPECT BETTER
MICROBA.COM
EXPECT BETTER
MICROBA LIFE SCIENCES LTD
© ALL RIGHTS RESERVED
Equity Raise
Section 4
18
MICROBA.COM EXPECT BETTER
Equity Raising Summary
Offer Structure and Size
• Microba is undertaking a non-underwritten institutional placement to raise approximately A$4 million (Placement), comprising 80 million fully paid
ordinary shares (New Shares), pursuant to the Company's existing placement capacity under ASX Listing Rule 7.1
• A non-underwritten share purchase plan targeting to raise up to A$1 million (SPP) to provide eligible existing shareholders in Australia and New
Zealand with the opportunity to each participate in subscribing for a maximum of A$30,000 New Shares,
(together, the Offer)
Offer Price
• A$0.05 per New Share, representing a:
– 20.6% discount to last close price of A$0.063 on 2 June 2026;
– 25.3% discount to the 5-day VWAP of A$0.067; and
– 25.9% discount to the 10-day VWAP of A$0.0675.
Share Purchase Plan
• The SPP will be offered on the same terms as the Placement being A$0.05 per New Share, and receive the 1:1 Attaching Options as referenced below
• The New Shares and Attaching Options under the SPP and placement will be offered under a transaction-specific prospectus pursuant to section 713
of the Corporations Act 2001 (Cth) (Prospectus).
• The New Shares and Attaching Options under the SPP will be subject to shareholder approval at the General Meeting.
Attaching Options
• New Shares issued under the Placement and SPP will include one (1) free attaching unlisted option for every one (1) New Shares Issued, exercisable
at A$0.0625, expiring three (3) years from the date of issue (Attaching Options).
• The Attaching Options under the Placement will be also offered under the Prospectus.
• All attaching options will be subject to shareholder approval at the General Meeting.
Use of Proceeds
• Proceeds from the Placement are intended to fully fund the group to cashflow break-even.
• Specifically, Placement proceeds will be applied to:
– Core diagnostics growth across Australia and the UK;
– Delivery of a category-defining new testing product;
– Strengthening working capital; and
– Costs of the Offer.
• Any funds raised under the SPP will be allocated to working capital
Joint Lead Managers and
Bookrunners
• Morgans Corporate Limited (Morgans) and Canaccord Genuity (Australia) Limited (Canaccord)
MICROBA.COM EXPECT BETTER
Timetable
Event Date
Record Date for entitlement to participate in SPP Thursday, 11 June 2026
Voluntary Suspension lifted and announcement to ASX of the Placement and SPP Friday, 12 June 2026
Settlement Date of New Shares (Placement) Wednesday, 17 June 2026
Issue of New Shares (Placement) Thursday, 18 June 2026
Lodgement of the Prospectus - SPP (Shares and Attaching Options) and the Attaching Options for the Placement Friday, 19 June 2026
Offers open under the Prospectus Friday, 19 June 2026
Dispatch Notice of Meeting (NoM) Tuesday, 23 June 2026
Offers close under the Prospectus Wednesday, 22 July 2026
Extraordinary General Meeting (EGM) - to approve all Placement Attaching Options and the New Shares and Attaching Options under the SPP Friday, 24 July 2026
Issue of New Shares under the SPP Offer and the issue of all Attaching Options under the Placement and SPP Wednesday, 29 July 2026
Commencement of trading of New Shares issued under the SPP Thursday, 30 July 2026
Any shares to be taken up by Directors under the Placement will be subject to approval at the EGM with the Shares and attaching options issued after the EGM date.
Capital structure at a glance
Corporate1
ASX code MAP
Market capitalisation¹ $38.36m
Shares on issue 608.96m
52-week low / high¹ $0.063 / $0.135
Cash balance (31 Mar 2026) $7.28m
Major shareholders²
Sonic Healthcare 21.68%
Perennial 12.02%
Mercer Investments (Australia) 6.37%
Thorney Investment Group 5.88%
SA Microba Holdings 5.50%
1 At 9 June 2026, 2 As per latest substantial shareholder notice lodged to the ASX. Figures predate the proposed equity raise. 21
MICROBA.COM
EXPECT BETTER
MICROBA LIFE SCIENCES LTD
© ALL RIGHTS RESERVED
Corporate transaction
update
Section 5
22
Recent corporate interest validates company value
Following an approach to Microba by a UK-based Private Equity fund, and after extensive due diligence, the company
agreed terms on an in-principle basis and subject to a number of conditions precedent (which included shareholder
approval) for the divestment of Microba’s Diagnostics and Supplements businesses.
The consideration would have exceeded the market capitalisation of Microba 1.
When the final deal structure was no longer in the best interest of shareholders, Microba chose not to proceed.
1 Price of the transaction was based on market capitalisation of company of $44m on 28 April 2026 if the transaction had completed based on the original agreed terms.
23
Contact
Head Office
Level 10, 324 Queen Street
Brisbane QLD Australia
Laboratory
Princess Alexandra Hospital
Woolloongabba QLD Australia
Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
Pasquale Rombola
Chair
pasquale.rombola@microba.com
24
Key Risks & Forward Financial Information Assumptions
KEY RISKS
Microba's financial position and performance, and the market price of Microba's shares may be adversely affected, sometimes materially, by a number of risk factors. Holders of Microba shares (Microba Shareholders) should accordingly be
aware that an investment in Microba carries a number of risks, some of which are specific to Microba and some of which are general risks that relate to the industries in which Microba operates or to listed securities generally. These risks mean
that the price and value of Microba shares may rise or fall over any given period. Some of these risks are beyond Microba's control.
Microba Shareholders should be aware of the following key risks (which are some, but not necessarily all of the risks) which may a
Share your feedback
Discover